SCHEMBL4617259

SCHEMBL4617259

COCCNS(=O)(=O)c1cc(S(=O)(=O)c2ccc(F)cc2)ccc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.56
USP2 O75604 1/20 0.56
SFRP1 Q8N474 1/20 0.56
ALDH1A1 P00352 8/20 0.54
BRD4 O60885 1/20 0.53
BRD2 P25440 1/20 0.53
BRD3 Q15059 1/20 0.53
LMNA P02545 5/20 0.52
HPGD P15428 2/20 0.52
KDM4E B2RXH2 2/20 0.52
MAPT P10636 2/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
HTT P42858 3/20 0.51
PKM P14618 3/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.50
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4618116 0.93 SFRP1 (0.54) SMN1; SMN2USP2SFRP1ALDH1A1BRD4
SCHEMBL4617775 0.89 SFRP1 (0.71) SMN1; SMN2SFRP1ALDH1A1BRD4BRD2
SCHEMBL20202311 0.87 ALDH1A1 (0.66) SMN1; SMN2USP2SFRP1ALDH1A1BRD4
SCHEMBL4618942 0.84 SFRP1 (0.53) SMN1; SMN2SFRP1ALDH1A1LMNAPKM
SCHEMBL4618887 0.84 SFRP1 (0.75) SMN1; SMN2SFRP1ALDH1A1BRD4BRD2
SCHEMBL4616704 0.82 SFRP1 (0.56) SMN1; SMN2SFRP1ALDH1A1LMNAMAPT
SCHEMBL4617591 0.82 ALDH1A1 (0.72) SMN1; SMN2SFRP1ALDH1A1MAPTMEN1
SCHEMBL4616336 0.82 SFRP1 (0.61) SMN1; SMN2SFRP1ALDH1A1LMNAKDM4E
SCHEMBL4616205 0.81 SFRP1 (0.55) SMN1; SMN2SFRP1ALDH1A1LMNAKDM4E
SCHEMBL6102760 0.81 SFRP1 (0.68) SMN1; SMN2SFRP1ALDH1A1BRD4BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 SMN1; SMN2 2404/4885USP2 2796/4885SFRP1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.